openPR Logo
Press release

Helix Research Center Announces Medical Research Services In OECD Countries

03-28-2011 12:36 PM CET | Health & Medicine

Press release from: Helix Research Center Ltd

Clinical Research,Healthcare,Education Services Worldwide

Clinical Research,Healthcare,Education Services Worldwide

Inspired by the relentless persuit of the Organisation for Economic Cooperation and Development (OECD), which was formed on September the 30,1961 by the combined efforts of erstwhile Organisation for European Economic Cooperation (OECC),the United States and Canada,inroder to promote policies that will improve the economic and social well being of the People around the World;especially the promotional activities pertaining to Healthcare,Research and Development (R&D) initiatives by Pharmaceutical,Medical Device,Biotechnology and Cosmetic Industry,Bioethics etc,UK based Helix Research Center Ltd has taken an initiative to provide Medical Research Services in the OECD Countries under similar Standard Operating Procedures (SOPs).Moreover,since OECD had formed Centre for Cooperation for with Non Members (CCNM),works closely with Council of Europe and has developed working relation with emerging Economies such as Brazil,Russia,India,China,South Africa (BRICS Countries),Indonesia etc,OECD region is indeed the 'Nucleus' for the World trade which is estimated to be around 80%.

Since the Research Personnel in the OECD Countries are thorough with the various Guidelines pertaining to Clinical and Non Clinical Research ,Viz-Declaration of Helsinki by World Medical Association,International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guidelines,WHO Ethical Standards and Procedures for Research With Human Beings,International Ethical Guidelines for Biomedical Research Involving Human Subjects by Council for International Organisations of Medical Sciences (CIOMS),Human Rights/Bioethics by United Nations Educational,Scientific and Cultural Organisation (UNESCO),Council Europe Bioethics Convention,OECD Biobank Guidelines,Guidelines and Regulations of Regulatory bodies of Member states,the Pharmacovigilance by Uppsala Monitoring Centre (UMC),the Protection of Human and Animal Rights and safety and well being of Trial subjects is assured and Quality Data generated during Clinical/Non Clinical Trials facilitates quicker Regulatory Approvals for introduction of new Medicines to the market.The 'Mutually Acceptable Data' (MAD) System introduced by OECD is one its Milestones that has Harmonised Good Laboratory Practices (GLP) across the Globe and saved time and money as well.

The Sophisticated Healthcare system in the OECD Countries provides excellent Central Lab and sample storage facilities.The highly skilled Doctors and the support staff can handle any Adverse Events/Severe Adverse Events and facilitate reporting of the same to Regulatory Authorities/National Pharmacovigilance Centers/UMC as per the GCP Guidelines.The Transport System within and across OECD Countries facilitates quicker to and fro shipping of the Investigational New Products as well as Laboratory samples.The measures being taken by Ministries of Health and their associated bodies in the OECD Countries to promote R&D Initiatives and to maintain the balance between Research activities and Protection of Clinical Trial Subjects is praiseworthy indeed.Many OECD Member States have formed Committees to prepare the Report on measures to be taken to promote Global Clinical Trials/New Drug Discovery.Various grants allotted and awarded for the Investigator-driven Research activities is an established fact amongst the Research Community.

It is an established truth that despite being developed economies and striving hard to ensure better quality of living;various forms of Cancers,Cardiovascular Diseases,Disorders of Nervous System,Mental disorders,Chronic Respiratory Diseases,Diabetes,Road Traffic Accidents,Musculoskeletal Disorders,Genito Urinary diseases,Digestive system Disorders,Infectious/Parasitic Diseases,Congenital anomalies,Neonatal conditions etc are rampant across the Globe and continue to cause Nightmares for the Health Administrators/Healthcare Policy makers in the OECD Countries.Hence,the Regulatory Authorities of the respective country are under tremendous pressure to promote Ethical Research whilst ensuring safety and well being of the Clinical /Non Clinical Research Subjects.
Due to recommendations of various experts,Professional Associations,Academia,Government Committees etc,the Process to Harmonise and Globalise Medical/Clinical Research has taken a momentum since a decade and the OECD Region provides 'Globalised' Clinical Trial environment indeed.The 'Expedited Review' System introduced by various Regulatory bodies in this region encourages the Clinical Trial Sponsors to plan and place many Global Trials

Helix Research Center has an expertise to provide entire spectrum Therapeutic as well as Scientific Research Services within the purview of the Rules and Regulations Pan OECD Region.Since various Government bodies/officials are always ready to render support for any Enterprise/Entrepreneur working hard to add some value to their community,the Management of Helix Research Center has a strong desire and Vision to establish World Standard Healthcare and Research facilities in this region.Since,ensuring strict GCP Compliance is most important than the Experiment/Science itself,Clinical Trial related issues continue to hit the Headlines of News Papers,TV and other electronic media almost everyday,there is a dire need to find a way to avoid Controversies pertaining to Biomedical Research activities in any part of the World.Since many UN bodies such as WHO,UNESCO and Non Governmental bodies associated with UN/WHO such as CIOMS ,Council of Europe,etc are playing a Key Role in promoting R&D,Healthcare etc,Helix Research Center makes a suggestion for creating a 'Scientific Committee' to review any Clinical or Non Clinical Protocol,much before an Investigational New Drug Application (IND) is filed by the Sponsor.Every Member of such a Scientific Committee will sign the CDA/NDA and hence there will not be scope for Breach of 'Confidentiality'.Thorough review of the Protocol by the highly qualified Members of the Committee might help the Sponsors,Regulatory Authorities to avoid Clinical Trial related embarrassment and Protect the Clinical Trial subjects by avoiding Adverse Events/Thalidomide like Disasters!

Helix Research Center is always keen to work with like minded Individuals,Groups,Associations,NGOs,etc to promote New Drug Discovery,Preventive&Curative Healthcare,conduct Patient Education Programs,Train the Research Personnel,Conduct Events/Seminars/Confefences etc in any part of the World.After all in the Scientific arena,'what is being done is most important than who is doing it'.This is an Era of Public Private Partnerships and in view of the highly strained World Economy,Cooperation,Collaboration,Symbiosis may offer some Solace!.

Helix Research Center Ltd is a London,UK headquartered MNC,Providing Clinical Research,Consulting,Educational ,Healthcare etc Services for the Biopharmaceutical,Medical Device and Cosmetic Industry and other R&D Promoters in Asia,Africa,Oceania,Europe,North America and South America.

Helix Research Center Ltd,
Office 4,
219 Kensington high street,
W8 6BD,London ,UK
+44 70 240 29790
Dr Venkateswar Rao G

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Helix Research Center Announces Medical Research Services In OECD Countries here

News-ID: 168428 • Views: 1025

More Releases from Helix Research Center Ltd

Clinical Research Practices Concept to Expedite Global Clinical Trials
Having analysed and understood the Non Clinical & Clinical Trial outsourcing trends in the Global Clinical Research arena and the challenges by being endured by the stakeholders of Research & Development Industry;Viz the Pharmaceutical,Medical Device,Biotechnology and Cosmetic Industry Worldwide , the issues such as Financial constraints,safety and well being of Trial subjects,Errors,Misconducts,negative talk about the Clinical Trial activity itself in one or the other media and the need for introducing
Harmonised GCP Training Courses Launched by Helix Research Center
Inspired by the initiative of Sponsors of ICH ( International Conference on Harmonisation of Technical Requirements for the Registration of Pharmaceuticals of Human Use) Viz,European Agency for the Evaluation of Medicinal Products ( EMEA),Japanese Ministry of Health,Labour and Welfare (JMHLW) and the US Food and Drug Administration (USFDA) , the Co Sponsors;Viz ,the European Federation of Pharmaceutical Industries' Associations (EFPIA),the Japanese Pharmaceutical Manufacturers Association (JPMA),the Pharmaceutical Research and Manufacturers of
Clinical Research Certificate Programs With Internship In India
It is an established fact that Clinical Research Industry is considered multibillion dollar industry and there can be no 'Recession' for the rapidly increasing dreadful diseases that cause high mortality and morbidity in almost every region of the World,irrespective any global economic slowdown/recession. But the Global Biopharmaceutical ,Medical Device and Cosmetic Industry and other Sponsors of R&D ( Research and Development) have been enduring many constraints including severe financial
Consulting,SMO & Site Support Services for the Global Clinical Trials
In view of the absolute necessity to ensure ,Safety and well being of Clinical Trial Subjects ,strict adherence to Good Clinical Practices Guidelines and Regulations governing Biomedical Research by Doctors of various Therapeutic areas such as Cardiology,Neurology,Oncology,Endocrinology,Pulmonology,Psychiatry,Obstetrics & Gynecology,Gastroenterology,Opthalmology,ENT,Internal Medicine,General Surgery etc,the need to produce quality data for a given study,reduce Regulatory delays,prevent avoidable errors and misconducts during a Clinical Trial,reduce the avoidable overheads for the Clinical Trial Sponsors such

All 5 Releases


More Releases for Clinical

Clinical solutions
Are you spending more time with yellow files than with patients? Healthbridge can change that with our intuitive and easy to use clinical platform that is designed specifically for the medical practitioner at the practice. smaller2 Easily access patient information Cloud-based technology enables you to store rich clinical information that can be easily accessed as and when you need it. Medical billing software innovation Become a paperless practice Create scripts, sick notes, and clinical notes electronically. Plus, have
Clinical Research and Clinical Trials Summit
Clinical Research 2019 has been designed in an interdisciplinary manner with a multitude of tracks to choose from every segment and provides you with a unique opportunity to meet up with peers from both industry and academia and establish a scientific network between them. We cordially invite all concerned people to come join us at our event and make it successful by your participation. This is the premier interdisciplinary forum for
Clinical Trial Management System
According to a new market report published by Persistence Market Research “Global Market Study on Clinical Trial Management System: Asia to Witness Highest Growth by 2019” the global clinical trial management system market was valued at USD 844.0 million in 2013 and is expected to grow at a CAGR of 14% from 2014 to 2019, to reach an estimated value of USD 1,848.5 million in 2019. Request Report TOC @ https://www.persistencemarketresearch.com/methodology/3017
Clinical Nutrition Conference 2018
Clinical nutrition is essential for patients in healthcare to deal with sickness, injuries, surgery and for proper recovery. It helps in preventing malnutrition, restoring body tissue and boosting energy and immunity in the body. It can be provided with a proper diet plan and feeding the patient with essential foods that revive the patient’s body the patient can also be given healthy supplements for proteins, vitamins etc. The preferred route
Clinical Communication
According to a recent market report published by Persistence Market Research titled “Clinical Communication and Collaboration Market: Global Industry Analysis (2012–2016) and Forecast (2017–2025),” revenue from the global clinical communication and collaboration market was US$ 138.5 Mn in 2012 and US$ 214.8 Mn in 2016, representing a CAGR of 11.6% from 2012 to 2016. This revenue growth is attributed to addition of new features in clinical communication and collaboration solutions.
Europe Clinical Nutrition Market
According to the report “Europe Clinical Nutrition Market,” published by Market Data Forecast, the global market is projected to reach USD 12.45 billion by 2021 from USD 9.65 billion in 2016, at a CAGR of 5.29% from 2016 to 2021. Clinical nutrition is the practice of analysing if a person is consuming an adequate amount of nutrients for good health. A clinical nutritionist is concerned with how nutrients in food are